A Review on FDA Approval of Lymphoma Drug Ukoniq (Umbralisib) And Its Withdrwal Due to Safety Concerns . (2022). Journal of Pharmaceutical Negative Results, 13(4), 1465-1474. https://doi.org/10.47750/pnr.2022.13.04.206 (Original work published 2022)